Tiansheng Pharmaceutical Group Co Ltd (002872) - Total Assets
Based on the latest financial reports, Tiansheng Pharmaceutical Group Co Ltd (002872) holds total assets worth CN¥2.65 Billion CNY (≈ $387.63 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Tiansheng Pharmaceutical Group Co Ltd (002872) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Tiansheng Pharmaceutical Group Co Ltd - Total Assets Trend (2012–2024)
This chart illustrates how Tiansheng Pharmaceutical Group Co Ltd's total assets have evolved over time, based on quarterly financial data. Check 002872 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Tiansheng Pharmaceutical Group Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Tiansheng Pharmaceutical Group Co Ltd's total assets of CN¥2.65 Billion consist of 25.7% current assets and 74.3% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 9.9% |
| Accounts Receivable | CN¥314.98 Million | 11.5% |
| Inventory | CN¥106.80 Million | 3.9% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥285.90 Million | 10.5% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Tiansheng Pharmaceutical Group Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 002872 stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tiansheng Pharmaceutical Group Co Ltd's current assets represent 25.7% of total assets in 2024, a decrease from 42.4% in 2012.
- Cash Position: Cash and equivalents constituted 9.9% of total assets in 2024, up from 7.8% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 10.0% of total assets, a decrease from 16.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 11.5% of total assets.
Tiansheng Pharmaceutical Group Co Ltd Competitors by Total Assets
Key competitors of Tiansheng Pharmaceutical Group Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $763.95 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
China | CN¥4.48 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
USA | $1.04 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Tiansheng Pharmaceutical Group Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.01 | 1.67 | 1.44 |
| Quick Ratio | 1.69 | 1.38 | 1.12 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥343.09 Million | CN¥279.11 Million | CN¥401.27 Million |
Tiansheng Pharmaceutical Group Co Ltd - Advanced Valuation Insights
This section examines the relationship between Tiansheng Pharmaceutical Group Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.83 |
| Latest Market Cap to Assets Ratio | 0.08 |
| Asset Growth Rate (YoY) | -2.7% |
| Total Assets | CN¥2.74 Billion |
| Market Capitalization | $229.41 Million USD |
Valuation Analysis
Below Book Valuation: The market values Tiansheng Pharmaceutical Group Co Ltd's assets below their book value (0.08x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Tiansheng Pharmaceutical Group Co Ltd's assets decreased by 2.7% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Tiansheng Pharmaceutical Group Co Ltd (2012–2024)
The table below shows the annual total assets of Tiansheng Pharmaceutical Group Co Ltd from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.74 Billion ≈ $400.38 Million |
-2.66% |
| 2023-12-31 | CN¥2.81 Billion ≈ $411.32 Million |
-5.35% |
| 2022-12-31 | CN¥2.97 Billion ≈ $434.58 Million |
-4.81% |
| 2021-12-31 | CN¥3.12 Billion ≈ $456.56 Million |
-14.42% |
| 2020-12-31 | CN¥3.65 Billion ≈ $533.52 Million |
-16.98% |
| 2019-12-31 | CN¥4.39 Billion ≈ $642.61 Million |
-6.04% |
| 2018-12-31 | CN¥4.67 Billion ≈ $683.93 Million |
-5.51% |
| 2017-12-31 | CN¥4.95 Billion ≈ $723.83 Million |
+45.83% |
| 2016-12-31 | CN¥3.39 Billion ≈ $496.35 Million |
+18.35% |
| 2015-12-31 | CN¥2.87 Billion ≈ $419.40 Million |
+14.87% |
| 2014-12-31 | CN¥2.50 Billion ≈ $365.12 Million |
+15.57% |
| 2013-12-31 | CN¥2.16 Billion ≈ $315.92 Million |
+23.80% |
| 2012-12-31 | CN¥1.74 Billion ≈ $255.19 Million |
-- |
About Tiansheng Pharmaceutical Group Co Ltd
Tiansheng Pharmaceutical Group Co., Ltd. engages in the pharmaceutical manufacturing and circulation activities. It offers products in various categories, including respiratory, cardiovascular and cerebrovascular, urinary system, gynecological, orthopedic, cardiology, diabetes, anesthetic, and others. It also provides traditional Chinese medicines and glucose injection. The company was founded in… Read more